Chemomab Therapeutics Ltd. (ANCN) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-K	10-K	10-K	20-F	20-F
Revenues [+]	0.0	0.0	0.0	0.4	0.0	18.8	9.3
Net interest income				0.4	0.0
Revenue growth			-100.0%	835.7%	-99.8%	102.3%
Cost of goods sold	8.6	4.3	1.1	0.0	0.0	0.0	0.0
Gross profit	-8.6	-4.3	-1.1	0.4	0.0	18.8	9.3
Gross margin				100.0%	100.0%	100.0%	100.0%
Selling, general and administrative [+]	13.0	6.2	1.3	6.2	5.5	3.2	2.3
General and administrative	13.0	6.2	1.3	6.2	5.5	3.2	2.3
Research and development	17.0	6.3	4.7	13.3	7.5	6.2	2.4
Other operating expenses	-66.4	-29.4	-7.1	-54.2	-26.5
EBITDA [+]	27.9	12.6	0.0	35.3	13.6
EBITDA growth	120.9%	52495.8%	-99.9%	160.1%	44.6%	102.3%
EBITDA margin				8990.8%	32340.5%	50.0%	50.0%
Depreciation and amortization	0.1	0.0	0.0	0.3	0.1
EBIT [+]	27.8	12.6	0.0	35.1	13.5	9.4	4.6
EBIT growth	121.0%		-100.0%	159.3%	43.9%	102.3%
EBIT margin				8919.3%	32183.3%	50.0%	50.0%
Non-recurring items				3.4
Interest expense				0.0	0.0
Interest expense				0.0	0.0
Other income (expense), net	0.4	-0.1	6.0	-4.6		0.1	0.0
Pre-tax income	28.2	12.5	6.0	27.1	13.5	9.5	4.6
Income taxes	0.5	0.0	0.0	0.0	0.3	-0.3	-0.1
Tax rate	1.9%	0.0%	0.0%	0.0%	2.3%
Net income	27.6	12.5	6.0	27.1	-13.8	9.8	4.7
Net margin				6901.8%	-32852.4%	52.2%	51.1%

Basic EPS [+]	$0.12	$0.06	$0.04	$0.79	($1.09)
Growth	102.0%	38.2%	-94.5%	-172.1%
Diluted EPS [+]	$0.12	$0.06	$0.04	$0.79	($1.09)
Growth	102.0%	38.2%	-94.5%	-172.1%

Shares outstanding (basic) [+]	227.6	207.5	136.8	34.4	12.6
Growth	9.7%	51.7%	297.0%	172.6%
Shares outstanding (diluted) [+]	227.6	207.5	136.8	34.4	12.6
Growth	9.7%	51.7%	297.0%	172.6%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.